IDEX BIOMETRICS ASA
Oslo, Norway, 7 January 2021: IDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider of advanced fingerprint identification and authentication solutions. CEO Vince Graziani and CFO Derek D’Antilio will participate at the 23rd Annual Needham Growth Conference on Wednesday 13 January 2021, which is being held as a virtual event.
Portfolio managers and analysts who would like to request a meeting with management should contact their Needham representative (conferences@needhamco.com ) or IDEX’s investor relations.
About IDEX Biometrics
IDEX Biometrics ASA is a leading provider of fingerprint identification technologies offering simple, secure and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings. We invent, engineer, and commercialize these secure and safe yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics
U.S. Investor Contact:
Brett L Perry, Shelton Group
E-mail: sheltonir@sheltongroup.com
Tel: +1 214 272 0070
Company Contacts:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 918 00186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd16.9.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Society of Actuaries16.9.2025 20:46:16 CEST | Press release
Society of Actuaries Announces Planned CEO Succession in 2026
Lehman Brothers UK Capital Funding LP16.9.2025 17:53:36 CEST | Press release
Lehman Brothers UK Capital Funding LP: Notice of Proposed Interim Payment
Sampo plc16.9.2025 17:10:00 CEST | Press release
Sampo prices the issuance of new Restricted Tier 1 notes
Ringkjøbing Landbobank A/S16.9.2025 17:00:58 CEST | Pressemeddelelse
Ringkjøbing Landbobank udsteder Tier 2-kapital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom